Literature DB >> 3767127

Comparison of tremor responses to orally administered albuterol and terbutaline.

J W Jenne, G Valcarenghi, W S Druz, P W Starkey, C Yu, T K Shaughnessy.   

Abstract

This study was designed to compare the initial tremor response to 4.0 mg albuterol and 5.0 mg terbutaline orally administered and to study the question of tachyphylaxis by rechallenge after 3 wk of maintenance dosing. Twenty fasting patients with severe COPD in whom orally administered sympathomimetics were withheld for 2 wk were challenged with single doses of each drug in a crossover, randomized fashion 1 wk apart. Then after a further 3 wk of dosing 3 times a day of the second medication (10 patients received each medication), they were challenged once more 16 h after the last dose. Rest and postural tremor were measured at zero and 2 h using an accelerometer affixed to the finger, and measurements of subjective tremor, tremor power spectrum, plasma cyclic AMP and lactate, and forced vital capacity were also made. Postural tremor increased from 25.05 to 36.20 relative units for albuterol, an increase of 11.15 units, and from 24.90 to 57.70 units for terbutaline, an increase of 32.80 units (difference significant at p = 0.01). Plasma cyclic AMP (p less than 0.01) and lactate (p = 0.05) increases were also less for albuterol, and the FEV1 and FVC responses, though about one third less, did not differ significantly. After 3 wk, mean baseline tremor for both drugs was elevated even 16 h after the last 3 times a day dosing (38.00 and 33.10) for albuterol and terbutaline (difference, NS), and responses were much less to the single tablet (3.40 and 9.10, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3767127     DOI: 10.1164/arrd.1986.134.4.708

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  6 in total

1.  Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; J B Palmer; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

3.  A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model.

Authors:  B Auclair; I W Wainer; K Fried; P Koch; T P Jerussi; M P Ducharme
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

4.  Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets.

Authors:  K Larsén; B Schmekel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; M K Charter; J B Palmer; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Neuropsychological dysfunction in asthmatic children.

Authors:  R D Annett; B G Bender
Journal:  Neuropsychol Rev       Date:  1994-06       Impact factor: 7.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.